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Abstract
OBJECTIVE: To observe the effect of the Traditional
Chinese Medicine, modified Taohongsiwu decoc-
tion, versus pyridoxine on patients with hand-foot
syndrome (HFS) from capecitabine, sorafenib, and
gefitinib chemotherapy for gastric, lung, breast, co-
lon, or rectal cancer. Also, to compare quality of life
of patients in each group.
METHODS: Patients were assigned randomly to
group A or B. Group A was given modified Taohong-
siwu decoction to soak hands and feet for 30 min,
once daily. Group B was given 100 mg pyridoxine
orally, twice daily. After a 2-week treatment, the
therapeutic effect was assessed by observing three
major symptoms, including pain, ulceration, and
muscular atrophy. This was assessed with the
HFS-14 questionnaire.
RESULTS: Significant differences were observed be-
tween the two groups in pain relief, and improve-
ment of daily life, walking, and interpersonal com-
munication (P<0.01). No significant differences in
driving ability or interpersonal relationships were
found. After 2 weeks, the effective rate was 88.3%
in group A, which was significantly higher than the
50% in group B (P=0.00).
CONCLUSION: Modified Taohongsiwu decoction is
effective in the treatment of patients with HFS. It
improves patients' quality of life according to the
HFS-14.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Hand-foot syndrome (HFS), also known as pal-
mar-plantar erythrodysesthesia, is a skin reaction that
appears on the palms and/or soles after using certain
chemotherapy drugs, including capecitabine, sorafenib,
and gefitinib. Most cases are associated with fluoroura-
cil, liposomal doxorubicin, or capecitabine. The inci-
dence of HFS is approximately 7.3%-63% .1 Patients
initially experience tingling or numbness in the fingers
and/or toes, and later swelling, redness, desquamation,
and tenderness or pain. In severe cases, the acute pain
and muscular atrophy lead to difficulty in movement,
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which influences patient quality of life (QOL). Unfor-
tunately, the mechanisms causing HFS have not been
elucidated. Therefore, effective methods to prevent and
cure HFS are not established aside from temporary dis-
continuation of chemotherapy agents and drug dosage
adjustment. Consequently, chemotherapeutic effect is
reduced.2,3 Pyridoxine (vitamin B6) is a common drug
to treat or prevent HFS. However, studies show that it
has no effect on HFS from liposomal doxorubicin.4
Moreover, a study on urea/lactic acid-based topical ker-
atolytic agent cream for external application for preven-
tion of HFS was also discouraging.5 With the wide use
of capecitabine, fluorouracil, and sorafenib, the inci-
dence of HFS is rapidly increasing. In this study, the
Traditional Chinese Medicine, modified Taohongsiwu
decoction, was examined for its effect on treating and
relieving the symptoms of HFS and improving QOL
of patients.
METHODS
Subjects
This study was designed as a double-blind, random-
ized, controlled trial (Figure 1). All patients gave in-
formed consent before participation, and the study was
approved by the Clifford Hospital Ethics Committee.
Before treatment, groups were randomized by the com-
puter in a ratio of 2∶1, for Traditional Chinese Medi-
cine or pyridoxine, respectively. Patients, males and fe-
males, 36-78 years old, were histologically confirmed
to have gastric, lung, breast, colon, or rectal cancer and
HFS symptoms. Randomization was stratified by can-
cer diagnosis (gastric, lung, breast, colon, rectal). All pa-
tients were randomized to receive either modified Tao-
hongsiwu decoction or comparable placebo (pyridox-
ine) in a double-blind method. Researchers (doctors)
and the participants (patients) were blinded to the na-
ture of the treatment each participant received.
The patients in group A were treated by soaking the af-
fected hands and feet in Taohongsiwu decoction for
30 min once a day. Patients in group B received 100 mg
vitamin B6 twice daily.
The dose of vitamin B6 was based on small case re-
ports and series that were available.6-8 One hundred pa-
tients were enrolled in total, with 60 in group A and
32 in group B. Eight patients were invaluable for HFS
assessment (Table 1). In group A, 12 of 60 patients
had gastric cancer (20%), 18 had lung cancer (30%),
12 had breast cancer (20% ), 12 had colon cancer
(20%), and 6 had rectal cancer (10%). In group B, 12
of 32 had gastric cancer (37.5%), 10 had lung cancer
(31.5%), 9 had breast cancer (28%), and 1 had colon
cancer (4%). According to the HFS grading scale9 (Ta-
ble 2), group A had 22 cases in grade I (36.7%), 28 cas-
es in grade II (46.6% ), and 10 cases in grade III
(16.7%). Group B had 10 cases in grade I (31.2%), 17
cases in grade II (53.2% ), and five cases in grade III
(15.6%).
Treatment
Modified Taohongsiwu decoction was composed of
Taoren (Semen Persicae) 30 g, Honghua (Flos Car-
thami) 30 g, Shudihuang (Radix Rehmanniae Praepara-
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32 cases were analyzed.
11 cases were recovered, 5 cases
effective, 10 cases ineffective, and 6
getting worse.
60 patients were assigned to the
treatment group which was treated in the
way of soaking the sick parts into the
Taohongsiwu Decoction for external
application.
The effect was evaluated after treatment
for 1 week and 2 weeks, and the a
3-month follow-up was performed. No
case was lost in the follow-up.
60 cases were analyzed.
41 cases were recovered, 12 cases
effective, 7 cases ineffective, and 0
getting worse.
The effect was evaluated after treatment
for 1 week and 2 weeks, and the a
3-month follow-up was performed. No
case was lost in the follow-up.
32 patients were assigned to the control
group which received Vitamin B6 for
oral taking.
92 patients were randomly
assigned by the computer in
accordance with 2∶1.
Figure 1 Flow diagram of the trial
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ta) 30 g, Danggui (Radix Angelicae Sinensis) 30 g, Ch-
uanxiong (Rhizoma Chuanxiong) 15 g, Baishao (Radix
Paeoniae Alba) 15 g, Guizhi (Ramulus Cinnamomi)
15 g, Chuanniuxi (Radix Cyathulae) 15 g, Gancao (Ra-
dix Glycyrrhizae) 6 g, and Dazao (Fructus Jujubae) three
pieces. Herbs were decocted for about 45 min. The de-
coction was used (group A) to soak affected hands and
feet, and hot water was added to keep the decoction
hotter than 39℃ during soaking, once a day, for 30 min
each time, with 7 days as one course.
The control group (group B) was orally administered
100 mg pyridoxine (vitamin B6) twice daily.
Both groups received a 2-week treatment. Effects
were evaluated after one and two courses of treat-
ment and an overall evaluation was conducted 3
months later.6-8
Statistical methods
The statistical software SPSS 16.0 (Chicago, IL, USA)
was used for variance analysis of experimental data and
the HFS-14 scale was used to measure the HFS-related
QOL impairment.10
RESULTS
All 60 patients in the treatment group (group A) re-
ceived the herbal decoction soaking-washing. Table 3
shows the effect of 1- and 2-week and 3-month treat-
ment, according to HFS-14.
The terms for effectiveness are defined as follows.
Cured: the pain, ulcers, and muscular atrophy disap-
peared, and the patient recovered. Effective: the pain,
ulcers, and muscular atrophy were relieved, but the pa-
tient still had numbness of extremities, and daily life
was influenced. Ineffective: the symptoms were not re-
lieved, the patient still had serious discomfort, and dai-
ly life was influenced. Worse: the symptoms worsened,
and the chemotherapy or biological target therapy was
ceased (Table 4).
Effect was evaluated by observing the three major
symptoms: pain, ulceration, and muscular atrophy.
After a 2-week treatment in group A, 41 patients recov-
ered, 12 saw effects, 11 saw no effects, and 0 got
worse. The effective rate was 88.3%. In group B, 11 pa-
tients recovered, 5 saw effects, 10 saw no effects, and 6
got worse. The effective rate was 50%. The difference
between groups in effective rate was significant (c2=
20.05, P=0.000) (Table 5, Figure 2).
DISCUSSION
Palmar-plantar erythrodysesthesia, or HFS, is a com-
mon toxic reaction to some chemotherapeutic agents.
Capecitabine, fluorouracil, sorafenib, and gefitinib,
which are used in chemotherapy and biological target
therapy for patients with malignant tumors, are the
most frequently implicated agents causing HFS. With
widened use of these drugs, the number of HFS cases
is increasing. The incidence of HFS in patients receiv-
ing capecitabine is 77.4%.11 There is a wide symptom-
atic spectrum attributed to HFS and symptoms pro-
gressively worsen. Patients initially experience itching
in their hands and/or feet, which progresses to hyper-
emia. Usually, hyperemia occurs on the hands, finger-
tips, and plantar surface and includes redness and swell-
ing. Then, symptoms progress to pain, and patients ex-
perience dysesthesia and coarse or chapped skin. Some
patients have blisters, desquamation, skin peeling and
exudation. In severe cases, muscular atrophy deprives
patients of normal life activities such as dressing, walk-
ing, or standing up.
HFS impairs patients' QOL, but there is no effective
preventative treatment.12 Discontinuation of drugs or
reduction of dose are the only cures but these decrease
Item
Case
Age (years)
Sex [n (%)]
Cancer type
[n (%)]
Chemotherapy
drug [n (%)]
Grade of HFS
[n (%)]
Category
-
-
Male
Female
Gastric
cancer
Lung cancer
Breast cancer
Colon cancer
Rectal cancer
Capecitabine
Sorafenib
Gefitinib
Grade 1
Grade 2
Grade 3
Group A
60
42-78
36 (60.0)
24 (40.0)
12 (20.0)
18 (30.0)
12 (20.0)
12 (20.0)
6 (10.0)
42 (70.0)
3 (5.0)
15 (25.0)
22 (36.7)
28 (46.6)
10 (16.7)
Group B
32
36-75
18 (56.2)
14 (43.8)
12 (37.5)
10 (31.5)
9 (28.0)
1 (4.0)
0 (0.0)
21 (65.6)
3 (9.4)
8 (25.0)
10 (31.2)
17 (53.2)
5 (15.6)
Table 1 Patient demographics
Notes: group A were treated by soaking the affected hands and
feet in Taohongsiwu decoction for 30 min once a day; group B
received 100 mg vitamin B6 twice daily. HFS: hand-foot syn-
drome.
Grade
1
2
3
Clinical symptom
Numbness, tingling,
painless erythema, and
swelling
Painful erythema and
swelling
Moist desquamation,
ulceration, blisters, and
sever pain
Functional
Discomfort that
does not disrupt
normal activities
Discomfort that
affects activities of
daily life
Severe discomfort,
inability to work or
perform activities
of daily living
Table 2 HFS grading
Note: the National Cancer Institute classification is adopted for
Hand-foot syndrome grading. HFS: hand-foot syndrome.
12
JTCM |www. journaltcm. com February 15, 2014 |Volume 34 | Issue 1 |
Zhao CL et al. / Clinical Study
drug effect, further lower patient QOL, and decrease
survival time. Nevertheless, it has been reported that af-
ter 1 month of vitamin E administration, 100 mg/day,
47% of HFS patients experienced symptom improve-
ment.13 Moreover, some traditional Chinese herbal for-
mulae documented in the ancient Chinese pharmaco-
poeia have been employed for HFS related to chemo-
therapeutic drugs. Wang et al 14 soaked and washed
HFS affected hands and feet with a herbal decoction
that dispelled wind and stopped itching. They found
that it was effective. Others have also used herbal de-
coctions to cool blood and dispel wind, with effective
rates higher than treatment with high-dose vitamin
B6.15 In addition, there are reports on the effect of oral
Chinese medicines on HFS. For example, one study
gave modified Buyanghuanwu decoction orally with an
effective rate of 42%.16 Shao17 studied oral Bazhen de-
coction, and found an effective rate as high as 73.3%.
In our study, we treated HFS patients with the Tradi-
tional Chinese Medicine, modified Taohongsiwu decoc-
Figure 2 Evaluation of effect after a 2-week treatment
Group A were treated by soaking the affected hands and
feet in Taohongsiwu decoction for 30 min once a day; group
B received 100 mg vitamin B6 twice daily.
Items
Pain
Difficulty in closing the door
Difficulty in preparing meals
Difficulty in daily actions
Difficulty in washing face and brushing teeth
Not able to drive the car
Difficulty in putting on socks or gloves
Difficulty in getting dressed
Difficulty in putting on shoes
Difficulty in standing
Difficulty in walking, even a short distance
Staying seated or lying down
Difficulty in falling asleep
Feeling suffering in work
No good relation with others
Before treatment
6
72
78
83
72
100
72
91
65
55
67
100
78
8
35
1-week
3
45
55
43
32
75
53
55
32
25
33
75
55
35
30
2-week
2
15
23
21
10
32
21
32
15
15
21
33
21
11
25
3-week
1
0
15
12
15
20
0
21
0
0
15
20
18
15
25
P value
<0.01
<0.01
<0.01
<0.01
<0.01
NS
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
NS
Table 3 Effect evaluated with HFS-14 for group A
Notes: a higher score indicates poorer quality of life. NS: not significant; HFS: hand-foot syndrome.
Effect
Recovery
Effective
Ineffective
Worse
Definition
The disappearance of pain, ulceration and muscular atrophy, etc., the patients recover to normal daily life.
There is obvious alleviation of pain, ulceration and muscular atrophy, etc., but the patients can still feel some unfitness
such as numbness.
There is no obvious alleviation of hand-foot syndrome symptoms and the patients has serious unfitness condition, which
badly influences the patients' daily work and life.
The hand-foot syndrome symptoms get worse, and the chemotherapy and biological target therapy have to be stopped.
Table 4 Evaluation of effect
Group
Group A
Group B
Recovery
41
11
Effective
12
5
Ineffective
7
10
Worse
0
6
Effective rate (%)
88.3
50.0
Table 5 Comparison of effect between groups
Notes: group A were treated by soaking the affected hands and feet in Taohongsiwu decoction for 30 min once a day; group B received
100 mg vitamin B6 twice daily.
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tion. Taohongsiwu decoction was recorded in Yi Zong
Jin Jian.18 After a 2-week treatment, the effective rate
was 88.3% , while it was only 50% in the control
group treated with vitamin B6. As evaluated with the
HFS-14 scale, the herbal treatment for soaking and
washing hands and feet was effective in relieving pa-
tients' pain. It was also effective at improving daily life
activities including: door closing; meal preparation;
face washing and teeth brushing; getting dressed and
putting on shoes, socks or gloves; walking; and falling
asleep. However, there were no significant improve-
ments in car driving or in personal communication.
Therefore, modified Taohongsiwu decoction relieves
pain and improves QOL in patients with HFS, ensur-
ing continuation of chemotherapy or biological target
therapy.
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